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The main objective of this study was to investigate the feasibility of using PharmGKB, a pharmacogenomic
database, as a source of training data in combination with text of MEDLINE abstracts for a text mining
approach to identiﬁcation of potential gene targets for pathway-driven pharmacogenomics research.
We used the manually curated relations between drugs and genes in PharmGKB database to train a sup-
port vector machine predictive model and applied this model prospectively to MEDLINE abstracts. The
gene targets suggested by this approach were subsequently manually reviewed. Our quantitative analysis
showed that a support vector machine classiﬁers trained on MEDLINE abstracts with single words
(unigrams) used as features and PharmGKB relations used for supervision, achieve an overall sensitivity
of 85% and speciﬁcity of 69%. The subsequent qualitative analysis showed that gene targets ‘‘suggested’’
by the automatic classiﬁer were not anticipated by expert reviewers but were subsequently found to be
relevant to the three drugs that were investigated: carbamazepine, lamivudine and zidovudine. Our
results show that this approach is not only feasible but may also ﬁnd new gene targets not identiﬁable
by other methods thus making it a valuable tool for pathway-driven pharmacogenomics research.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Adverse Drug Reactions (ADRs) are responsible for 5.3% of hos-
pital admissions and cost over 100 billion dollars per year due to
prolonged hospital stays and decreased productivity making
reduction in ADRs one of the top priority areas in health care and
health services research [1]. One of the promising areas in biomed-
ical research that can help reduce ADRs and enable more precise
and rational dosing of medications based on individual patient
characteristics is pharmacogenomics. Inter-individual variability
in genetic makeup contributes signiﬁcantly to observed variation
in treatment response. The exact same dose of a medication may
be ineffective in one individual and highly toxic in another due
to this variation in treatment response. Some of the differences
in drug response are due to inherited genetic polymorphisms in
genes involved in absorption, distribution, metabolism and
excretion (ADME) of drugs. Presence of genetic polymorphisms in
the ADME genes can contribute to inter-individual differences in
drug levels and hence response and/or toxicity. Additionally,
genetic polymorphisms in drug targets and downstream signaling
pathways (pharmacodynamics) could impart therapeutic response.ll rights reserved.
ensford Hall, 308 Harvard St.
).For example, differences in genetically conditioned drug metabo-
lism were found to be responsible for the central nervous system
toxicity in some patients treated with standard doses of an anti-
neoplastic agent ﬂuorouracil. These patients had an inherited deﬁ-
ciency in dihydropyrimidine dehydrogenase, an enzyme that
metabolizes ﬂuorouracil. Findings like these have given rise to
the ﬁeld of pharmacogenomics and individualized medicine [2].
Two major approaches for studying the relationship between
genes and the variability in drug-response are genome-wide asso-
ciation studies (GWASs) and pathway driven approaches.
GWAS approaches explore the association between drug
response and genome-wide genetic variation. However, one of the
challenges for most GWAS studies is the high rate of false positives
due to massive multiple comparisons made within smaller
underpowered studies. In contrast, pathway driven approaches to
studying the relationship between genes and the variability in
drug-response require identiﬁcation of candidate genes and/or
pathways known to be important for drug pharmacokinetics and
pharmacodynamics.While a large amount of information necessary
to identify biologically plausible gene targets is contained in
curated databases such as PharmGKB, much of this information
still remains ‘locked’ in the unstructured text of biomedical
publications. Emerging scientiﬁc evidence does not become imme-
diately available in curated databases such as PharmGKB and is
likely to appear earlier in unstructured text resources such as
1 http://cpansearch.perl.org/src/TPEDERSE/Text-NSP-1.21/bin/utils/stoplist-
nsp.regex
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tify these candidate genes and/or pathways in published literature
is an important area of research.
A large body of work in text mining and biomedical natural lan-
guage processing (NLP) has been dedicated to extracting useful
information from the pharmacogenomic literature (see Garten,
Coulet and Altman [3] for a comprehensive review). Several studies
speciﬁcally have examined the use of text mining methods such as
automatic text categorization from PharmGKB and MEDLINE ab-
stracts to automatically identify and categorize relations between
genes, drugs and disorders [4,5]. The study by Garten, Tatonetti
and Altman [5] introduces a method by which a text processing
system Pharmspresso [4] was used to identify pharmacogenomic
relationships between genes and drugs extracted from full text of
biomedical articles. Pharmspresso-extracted drug–gene relations
encoded at a single sentence level were then used to automatically
generate a network graph of drug–gene interactions. The output of
Pharmspresso was thus used in a network analysis algorithm
PGxPipeline that leverages the network connectivity to score the
propensity of the genes to modulate drug response. The creation
of the network using the automated approach based on
Pharmspresso was subsequently compared to a network created
from the manually curated PharmGKB database and found to be
roughly equivalent. However, when the authors evaluated the
performance of Pharmspesso independently of the PGxPipeline,
they found that Pharmspresso identiﬁed 5312 pharmacogenomic
relations, while PharmGKB contained 1782 relations with an over-
lap between the two sources of 1157. These results show that
Pharmspresso is a relatively sensitive (recall of 65%) but not highly
speciﬁc (precision of 22%) tool for extracting individual drug–gene
relations. Similarly to PGxPipeline but without the use of free-text
extraction, Hansen et al. [6] have developed an approach to using
structural similarity between drugs and information on their inter-
actions contained in structured form in PharmGKB to train an
automatic classiﬁer for predicting the most likely novel gene can-
didates that may interact with drugs of interest. Another study by
Coulet et al. [7] relied on text mining and Natural Language Pro-
cessing techniques to extract drug–gene relation information from
MEDLINE to construct an ontological network of relations that may
be used in guiding the curation of pharmacogenomic resources
such as PharmGKB.
In our current study, we also investigated the use of text mining
algorithms for extracting pharmacogenomic relations from the
biomedical literature. However, the main difference between our
approach and that of Garten et al. [5] is that we used the manually
curated knowledge of drug–gene relations and linked this to
PubMed abstracts contained in PharmGKB itself to train a fully
supervised machine learning classiﬁer using the text of the ab-
stracts as a source of training features and PharmGKB-deﬁned rela-
tions as the source of category information (related vs. unrelated).
The main objective of our study is to investigate if MEDLINE ab-
stracts with mention of both drugs and genes contain lexical and
semantic indicators of either presence or absence of a functional
relationship between the drug–gene pair that may be used to iden-
tify biologically plausible gene targets. Our hypothesis is that the
language in the MEDLINE abstract that surrounds the mention of
drugs and genes (lexical context) is predictive of whether the ab-
stract as a whole is asserting some form of relationship between
the drug and the gene and is generalizable across multiple drugs.
If the context is indeed generalizable and can be modeled with
standard machine learning approaches, then it would be feasible to
construct a tool that can be used to examine MEDLINE abstracts on
a regular basis (or on demand) to classify abstracts containing
drug–gene pairs as related or unrelated in order to make sugges-
tions for possible gene targets for pathway driven pharmacoge-
nomic research.2. Methods
In this paper, we describe the use of PharmGKB to both train
and evaluate simple automatic drug–gene relationship classiﬁers
and present the results of a prospective evaluation study in which
the gene targets identiﬁed by our approach were examined by
pharmacogenomics experts using three drugs: carbamazepine,
lamivudine and zidovudine. The choice of these speciﬁc drugs
was motivated by the fact that their pathways have been recently
analyzed by our group, but the results of the analysis have not yet
been included in PharmGKB. The overall study design is illustrated
in Fig. 1.
2.1. Data
We used 822 drugs and 2247 genes labeled as ‘Related’ (those
marked as ‘Related’ or ‘Positively Related’) or ‘Unrelated’ (those
marked as ‘Negatively Related’, ‘Discussed’, or ‘Not Related’) in
PharmGKB. While these relations in PharmGKB are not always
consistently labeled, generally, positively related drug–gene pairs
indicate that there is evidence for a pharmacokinetic or pharamco-
dynamic relationship between the gene and the drug while a
negatively related pair indicates that the drug has been found to
have no interaction with the target gene and should, therefore, be
treated as ‘Unrelated’. The dataset consists of 9317 instances of
drug–gene pairs and the MEDLINE abstracts in which the pairs
occurred where each drug contained on average 11.3 instances
with a maximum of 394 (methotrexate) and a minimum of 1
(4-methylthioamphetamine).
2.2. Machine learning
Apart from the choice of the learning algorithm, two additional
processes are generally important in the context of text mining:
feature extraction and feature selection. Feature extraction refers
to the process of identifying relevant features in unstructured text.
Feature sets extracted from text can be very large, especially if a
non-selective feature extraction approach such as bag-of-words
is used. Selecting features that are most relevant and predictive
of the categories into which text is being categorized has been
shown to improve classiﬁcation accuracy [8].
2.2.1. Feature extraction
We explored the use of lexical features in a supervised learning
approach to labeling the drug–gene pairs as related or unrelated
using the support vector machine (SMO) from theWEKA data-min-
ing package [9].
Lexical features consisted of words or n-grams (sequences of
words) that frequently occured in the training data. We used uni-
grams (single words – equivalent to the bag-of-words approach)
and bigrams (two word sequences) in our current study, but with
larger datasets it may be beneﬁcial to experiments with larger
n-gram sizes. The names of the drugs and the genes found in all
PharmGKB drug–gene pairs were excluded from modeling to make
it context independent of any speciﬁc drug–gene pair in order to be
able to apply the resulting model prospectively to any drug–gene
pair. These drug and gene names were excluded by removing them
from the text of MEDLINE abstracts prior to modeling. The non-
content words (stopwords) are not included as features. The
stopword list used in these experiments contained 9900 general
English non-content words1. We used two frequency cutoffs to
determine if a unigram or bigram should be included in the feature
Fig. 1. Overall study design.
2 http://mbr.nlm.nih.gov/index.shtml
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ber of times in which a unigram or bigram occurred in the same ab-
stract as the drug–gene pair. For this work, we used a conservative
cutoff of two for both unigrams and bigrams. Thus, for example in
(1), the set of unigrams included, evidence, suggests, substrates and
induced.
(1) Evidence suggests that CYP2C9 substrates may also be induced
by carbamazepine.
2.2.2. Feature selection
We relied on WEKA’s implementation of the Information Gain
feature selection method. Information gain is a measure of the
contribution of each predictive feature to correctly predicting
the category [9]. Information gain reﬂects the degree by which
the uncertainty/entropy associated with determining the correct
classiﬁcation category is reduced by learning the value of a given
variable. This measure is frequently used in machine learning to
determine which features or sets of features to use for automatic
categorization. In our case, the information gain from a single
word for the related or unrelated categories would be zero if
there is no contribution of the feature to distinguishing between
related and unrelated exemplars, thus we used this as the thresh-
old to select only those features with positive contribution. Infor-
mation gain is a convenient feature selection method as its
computation is relatively fast and thus lends itself better to clas-
siﬁcation problems that involve large numbers of features and
multiple iterations; however, other more sophisticated feature
selection methods may result in further improvements in classiﬁ-
cation results.
2.3. Evaluation platform
We evaluated our approach using two methods: (a) hold-one-
out evaluation using only PharmGKB data and (b) prospective
extraction of drug–gene relations from MEDLINE with subsequent
manual validation.2.3.1. PharmGKB-based evaluation
We evaluated our approach using a modiﬁcation of the hold-
one-out validation method as illustrated in Fig. 1. In this method,
all available data were divided into 822 blocks where each block
was associated with a speciﬁc drug. We then tested our method
using one held-out drug-block, training on the remaining 821
drug-blocks. This procedure was repeated for each of the 822 drugs
such that each drug-block has been used as test data exactly once
with the remaining data used as training data. The operating char-
acteristics (sensitivity, speciﬁcity, positive and negative predictive
value) were averaged over all 822 blocks. Many of the drug blocks
contained very few instances of drug–gene relations that could
potentially result in biased overall estimates. To examine the im-
pact of this potential source of bias, we also averaged the results
over the top 15 drug blocks containing more than 20 samples.
The process of hold-one-out validation on a large number of drugs
was time consuming; therefore, we experimented with different
feature extraction methods (unigrams vs. bigrams) on a smaller
random sample of 110 drugs rather than the entire set of 822 drugs.2.3.2. Prospective manual evaluation
We also evaluated our approach prospectively by applying a
support vector machine model trained on all 822 drug blocks to
classify all available 2010 MEDLINE Baseline2 abstracts in which
we found at least one mention of carbamazepine, lamovudine or
zidovudine and any of the 2247 the gene names contained in Phar-
mGKB. At this preliminary evaluation stage, we used a simple string
matching approach to identifying drug and gene names but we are
aware that drug and gene names can be ambiguous and that more
sophisticated approaches to their identiﬁcation exist [10]. At this
point in our study we wanted to be as inclusive of the potential gene
targets as possible and thus relied on disambiguating gene names
(e.g. CAT – in the sense of ‘‘CAT scan’’ vs. ‘‘chloramphenicol acetyl
transferase’’) during the manual evaluation step rather than trying
to ﬁlter out non-gene senses prior to evaluation.
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automatically classiﬁed as related to the drug and presented these
results to a set of three reviewers with expertise in pharmacoge-
nomics. The experts have been involved in the pathway driven
analysis of these three drugs and thus were familiar with the drugs
and the gene candidates that were included in the drugs’ metabolic
pathways. In fact, the drugs for this evaluation were speciﬁcally
selected from a set of drugs whose pathway information has been
recently submitted to PharmGKB but had not appeared in the snap-
shot of the database used in our study. These reviewers were asked
to mark each drug–gene pair hypothesized to be related by our
automatic classiﬁcation approach as related or unrelated. Using this
evaluation approach we were only able to estimate the positive
predictive value (PPV); however, the intended practical use of our
approach is to provide pharmacogenomics researchers with recom-
mendations for possible gene targets to be examined during the
pathway driven analysis. Thus, we consider the PPV to be of more
practical signiﬁcance than any other operating characteristics. The
intent of this evaluation step was also to determine if the reviewers
with expertise in the pharmacogenomics of the three drugs of
interest would ﬁnd any related drug–gene pairs that they would
not have been aware of otherwise.Table 1
Entries in PharmGKB for carbamazepine, zidovudine and lamivudine existing prior to train
(classiﬁer result).
Carbamazepine (Gene: Relationshipa) Zidovudine (Gene: Relations
Gene Relation found
in PhGKB
Classiﬁer
result
Gene Relation fou
in PhGKB
ABCB7 Unrelated Unrelated ABCC5 Unrelated
ABCC2b Related Unrelated SLC22A1 Unrelated
ABCG2 Unrelated Unrelated SLC22A11 Unrelated
CYP2C8 Related Unrelated SLC22A2 Unrelated
CYP39A1 Unrelated Unrelated SLC22A3 Unrelated
EPHX1 Related Unrelated SLC22A7 Unrelated
GSTM1 Unrelated Unrelated SLC28A1 Unrelatedc
GSTT1 Unrelated Unrelated TK1 Unrelated
NR1I2 Unrelated Unrelated UGT2B7 Related
NR1I3 Unrelated Unrelated ABCG2 NA
RALBP1 Unrelated Unrelated AMT NA
SLC22A5 Unrelated Unrelated ATP7A NA
SLCO1A2 Unrelated Unrelated B2M NA
SULT1A1 Unrelated Unrelated CCR5 NA
CYP3A5 Related Related CXCR4 NA
CYP3A7 Related Related HFE NA
HLA-B Related Related SLC28A1 NA
SCN1A Related Related TG NA
ABCB1 Related Related UGT1A7 NA
CYP1A2 Related Related UGT1A9 NA
CYP2B6 Related Related
CYP2C19 Related Related
CYP2E1 Unrelatedc Relatedc
CYP3A Unrelatedc Relatedc
CYP3A4 Related Related
CHRNA4 NAd Related
CSTB NA Related
CYP3A NA Related
CYP2E1 NA Related
HSPA1A NA Related
IMPA2 NA Related
MECP2 NA Related
MIP NA Related
MPO NA Related
UGT1A7 NA Related
Total PharmGKB: 12 related and 13 unrelated Total PharmGKB: 1 related a
a If the gene was marked as ‘‘Related’’ in at least one abstract in PharmGKB, we treat
b Disagreements between the content of PharmGKB and our automatic classiﬁcation
c Designates disagreements where the a gene-drug pair was labeled in PharmGKB as U
conﬁrmed.
d NA indicates that the snapshot of PharmGKB that was used in this study did not coBased on the results of the manual annotations, we conducted a
sensitivity analysis in which we calculated PPV with and without
ﬁltering the output of the automatic classiﬁer for gene names. At
this preliminary stage, the ﬁltering consisted on manually examin-
ing each gene name acronym that was marked as related to each of
the three drugs in the context of the abstract in which the acronym
was found. If the context of the abstract suggested that the
acronym did not represent a gene name, that instance was then
removed from the classiﬁer output and was not included in
calculating the ﬁltered PPV value. Thus the ﬁltered PPV value
represents an estimate of the automatic classiﬁer performance
subsequent to a highly accurate gene-name identiﬁcation
algorithm. We report both ﬁltered and unﬁltered PPV values in
the Results section.2.3.3. Comparison to existing PharmGKB entries
In addition to the manual validation described in the previous
section, we also compared the output of our classiﬁcation approach
to the contents of PharmGKB with respect to each of the three
drugs. The entries contained in the snapshot of PharmGKB that
was used to train the automatic classiﬁer are shown in Table 1.ing automatic classiﬁers (PhGKB) compared to results of unigram-based classiﬁcation
hip) Lamivudine (Gene: Relationship)
nd Classiﬁer result Gene Relation found
in PhGKB
Classiﬁer
result
Unrelated ABCC4 Related Unrelated
Unrelated ABHD2 Unrelated Unrelated
Unrelated ACVR2B Unrelated Unrelated
Unrelated CDC34 Unrelated Unrelated
Unrelated EREG Unrelated Unrelated
Unrelated KHDRBS3 Unrelated Unrelated
Relatedc RORA Unrelated Unrelated
Unrelated SLC22A1 Unrelated Unrelated
Related SLC22A2 Unrelated Unrelated
Related SLC22A3 Unrelated Unrelated
Related ABCG2 NA Related
Related CYP1A2 NA Related
Related CYP2C19 NA Related
Related DDC NA Related
Related HFE NA Related
Related SLC28A1 NA Related
Related
Related
Related
Related
nd 9 unrelated Total PharmGKB: 1 related and 9 unrelated
ed that gene as ‘‘Related’’.
approach are highlighted in bold type face.
nrelated but was found to be Related by our approach and subsequently manually
ntain these associations found by our approach and manually conﬁrmed.
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3.1. PharmGKB-based evaluation
The performance of the algorithms was evaluated using stan-
dard measures of sensitivity and speciﬁcity as well as positive
and negative predictive value (PPV/NPV) to reﬂect for variable
prevalence of categories in the individual drug datasets.
Top ﬁfteen drugs with at least 20 instances in the PharmGKB
database are summarized in Table 2 along with means for two
other sets consisting of a random sample of 110 drug blocks used
to compare unigram and bigram feature extraction methods and
a full set of all 822 drugs. The detailed results for each drug in
the full result set are available at http://rxinformatics.umn.edu.
The results in Table 2 for the random sample of 110 drug blocks
show that the classiﬁers trained on unigrams were on average
more speciﬁc than the classiﬁers trained on bigrams (0.69 vs.
0.46), while the latter were more sensitive (0.96 vs. 0.85). Thus
for the next step in our evaluation involving human review of po-
tential gene targets classiﬁed as ‘‘related’’ by the automatic classi-
ﬁer, we took into account the ‘‘related’’ category prevalence and
selected the more speciﬁc unigram classiﬁer that yielded slightly
higher PPV of 0.91 vs. 0.89 obtained with the classiﬁer trained on
bigrams.3.2. Prospective manual evaluation
Evaluating the automatic classiﬁer approach on a larger set of
only related drug–gene pairs for PPV resulted in estimates shownTable 2
Comparison of SMO performance with several feature extraction methods.
Drug # of instances Classiﬁcation decisions
(pos/neg)
Baseline
(Majority C
PPV/NPV
Warfarina 232 217/15 0.94/0
Tamoxifen 110 66/44 0.60/0
Gemcitabine 87 71/16 0.82/0
Tacrolimus 63 59/4 0.94/0
Simvastatin 62 46/16 0.74/0
Vincristine 50 49/1 0.98/0
Cytarabine 46 254/22 0.52/0
Busulfan 37 37/0 1/0
Thioguanine 30 28/2 0.93/0
Sorafenib 28 28/0 1/0
Trastuzumab 28 23/5 0.82/0
Venlafaxine 28 22/6 0.79/0
Sertraline 27 13/14 0.48/0
Tolbutamide 26 25/1 0.96/0
Sirolimus 25 22/3 0.88/0
Top 15 mean 59 48.67/9.93 0.82/0.00
Random 110 mean 12 8.82/3.22 0.73/0.00
All 822 mean 11 8.82/3.22 0.82/0.76
a Drug datasets are sorted in the descending order of the number of instances.
b NA indicates drugs that did not have any instances in one of the two categories.
Table 3
Results of prospective manual evaluation for carbamazepine, lamivudine and zidovudine.
were initially identiﬁed as gene names but removed after their meaning was determined
Drug name Number of unique drug–
gene pairs found in
MEDLINE
Number of automatically
determined categories
(Related/Unrelated)
Numb
marke
expert
Carbamazepine 157 54/103 18
Lamivudine 83 16/67 6
Zidovudine 98 21/77 11in Table 3. For carbamazepine, the overlap between the set of genes
labeled by the automatic classiﬁer as ‘‘related’’ and those labeled as
‘‘related’’ in the manually curated PharmGKB database contains
nine gene names. As evident from Table 3, the automatic classiﬁer
‘‘suggested’’ 54 gene targets for this drug, of which 18 were
deemed by at least one expert as relevant.
Thus the classiﬁer effectively ‘‘discovered’’ nine new relevant
gene targets (100% increase relative to information contained in
PharmGKB) and missed three gene targets that were in PharmGKB.
For zidovudine, PharmGKB contained only one ‘‘related’’ gene tar-
get and this gene was also identiﬁed as ‘‘related’’ by the automatic
classiﬁer. However, the classiﬁer suggested a total of 21 targets,
eleven of which were deemed by experts to be relevant resulting
in ten new automatically ‘‘discovered’’ targets (1000% relative in-
crease). A slightly different result was obtained with lamivudine
– PharmGKB contained one related gene that was missed by the
automatic classiﬁer for reasons discussed in the Discussion section.
However, the automatic classiﬁer produced a total of 16 new tar-
gets, six of which were deemed by experts to be relevant thus
resulting in all six being novel viable targets not present in
PharmGKB (600% relative increase).3.3. Qualitative evaluation of the genes found with our approach
We conducted a qualitative analysis of two anti-retroviral
medications we have investigated in this study – zidovudine and
lamivudine. The list of genes indicated by our approach as poten-
tially related to the drug was manually examined by experts in
pharmacogenomics (JL, VL, YG, NB) to identify the ‘‘novel’’ geneslass)
Unigram-based classiﬁer Bigram-based classiﬁer
Sens. Spec. PPV/NPV Sens. Spec. PPV/NPV
0.89 0.73 0.99/0.33 0.99 0.73 0.98/0.85
0.74 0.63 0.75/0.62 0.97 0.18 0.64/0.80
0.73 0.19 0.8/0.14 1 0.19 0.85/1
0.95 0.75 0.98/0.5 1 0.25 0.95/1
0.74 0.5 0.81/0.4 1 0.25 0.79/1
0.98 1 1/0.5 1 0 0.98/0
0.96 0.68 0.77/0.94 1 0.68 0.77/1
0.59 NAb 1/0 0.95 NA 1.00/0
0.61 0 0.89/0 1 0 0.923/0
0.93 NA 1/0 0.93 NA 1/0
0.96 0.2 0.85/0.50 1 0.2 0.85/1
0.78 1 1/0.55 1 0.67 0.92/1
0.77 0.93 0.91/0.81 0.92 0.93 0.92/0.93
0.92 1 1/0.33 0.8 0 0.95/0
1 0.33 0.92/1 1 0 0.88/0
0.83 0.61 0.91/0.44 0.97 0.31 0.89/0.71
0.85 0.69 0.88/0.61 0.98 0.46 0.83/0.91
0.86 0.71 0.82/0.77 NA NA NA
The results are shown before and after manually resolving ambiguous acronyms that
to be something other than a gene name.
er of instances
d as ‘Related’ by
s
PPV before resolving
gene-name
ambiguity (%)
Number of
false gene
names
PPV after resolving
gene-name
ambiguity (%)
33 19 51
38 7 67
52 8 85
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identiﬁed nine genes (ABCG2, ATP7A, CCR5, HFE, TG, SLC28A1 and
UGT1A7, UGT1A9, UGT2B7) that were related to zidovudine.
Manual evaluation of the literature annotations provided strong
evidence for these genes in zidovudine pharmacokinetic and
pharmacodynamic pathway. Fig. 2 shows an example of a
pathway-driven analysis for zidovudine that was performed inde-
pendently of the current study. The targets along the pathways
shown in Fig. 2 have been experimentally conﬁrmed and recently
submitted to PharmGKB. The thick arrows in Fig. 2 indicate some
of the potential targets that were suggested by the automatic
classiﬁcation approach. Some of the overlapping genes identiﬁed
by both methods include UGT2B7, SLC28A1 and ABCG2. Addition-
ally our analysis identiﬁed some new genes such as HFE, hemato-
chromatosis gene, which has been implicated in antiretroviral
treatment induced neuropathy (PMID: 18419350). It is possible
that manual analysis to identify candidate PK/PD pathway genes
for zidovudine would have missed association of this gene with
the drug-induced adverse reaction.
Similarly our analysis identiﬁed four genes that were related to
lamivudine, another anti-retroviral drug. These included drugFig. 2. Illustration of the metabolic pathway analysis for zidovudine withtransporters ABCG2 and SLC28A1, and drug metabolizing enzymes
CYP1A2 and CYP2C19.4. Discussion
Wehave presented a novel approach for using standardmachine
learning and data mining techniques to leverage the existing man-
ually curated pharmacogenomics information contained in Phar-
mGKB. The results of the hold-one-out evaluation suggest that
contextual information contained in MEDLINE abstracts captured
with a simple bag-of-words approach can be used to determine if
the abstracts containing mentions of medications and genes pro-
vide evidence of some form of relatedness between the gene and
the drug. The fact that the mean sensitivity and speciﬁcity charac-
teristics for all 822 drug blocks are comparable to the results
obtained with the top 15 drug blocks with more than 20 training
samples in them alleviate our initial concerns with relatively small
numbers of samples available for each drug. The comparison be-
tween two feature extraction methods – one based on unigrams
and the other on bigrams – suggests that the unigram approach isthick arrows indicating targets identiﬁed by the automatic classiﬁer.
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an application where the automatic classiﬁcation approach is used
to suggest potential gene targets, it may be beneﬁcial to use the
unigram feature set on drugs with better known metabolic path-
ways (potentially large numbers of MEDLINE abstracts) in order
to reduce the investigator’s workload. However, in situations where
it is more important to capture as many potential gene targets as
possible regardless of the workload involved in ﬁltering out false
positives, it may be more beneﬁcial to use the bigram feature set.
Applying our unigram-based approach trained on PharmGKB in
a simulation of a ‘‘prospective’’ study to all of MEDLINE abstracts
resulted in ﬁnding many more potentially relevant gene targets
that were deemed to be useful by pharmacogenomics experts.
The practical signiﬁcance of these ﬁndings is that this approach
may be used as a way to recommend potential gene targets to
support the initial stages of pathway driven pharmacogenomics
research on an on-going basis with little or no human intervention
aside from the data being entered into PharmGKB. Since our
approach is fully automated, it can easily keep up with the rapid
growth of both PharmGKB and the MEDLINE abstracts repository.
Our method may be used to provide potentially complementary
information to other manually or semi-automatically curated
resources for pharmacogenomics and drug metabolism research
such as those provided by the Ingenuity Systems (http://www.
ingenuity.com/) and SuperCYP (http://bioinformatics.charite.de/
supercyp/). Another potential application of our approach is in
combination with Pharmspresso or other rule-based text mining
algorithms providing input to network analytic systems such as
PGxPipeline.
Our methodology may also be useful as a veriﬁcation mecha-
nism in helping investigators identify potential problems with
the evidence provided for the presence or absence of a relationship
between drugs and genes. For example, Table 1 shows that genes
CYP2E1 and CYP3A were originally entered into PharmGKB as
unrelated to carbamazepine and the gene SLC28A1 was marked
as unrelated to zidovudine; however, our automatic classiﬁcation
approach marked these drug–gene pairs as related and this was
subsequently conﬁrmed by manual review. These examples
demonstrate that scientiﬁc knowledge of the interactions between
drugs and genes is in constant ﬂux and accurate and up-to-date
information extraction requires ﬂexible and scalable text mining
methods to keep up with the rapid growth of evidence presented
in biomedical literature.5. Limitations
For the work presented in this paper we relied exclusively on
PharmGKB and MEDLINE as sources of training and testing data.
Other sources containing text and information useful for our ap-
proach exist and may be utilized. For example, MEDLINE abstracts
may be complemented with the full text of biomedical articles in
PubMed Central and other repositories. Our methodology may
need to be modiﬁed to work on the full text of biomedical articles
and will likely need to take into account article section
information.
For lamivudine, the snapshot of PharmGKB database that we
used for this study contained only one gene marked as ‘‘related’’
– ABCC4. Our classiﬁcation approach failed to ﬁnd this relationship
because neither the gene name ABCC4 or MRP4 were used in any of
the available PubMed abstracts. Interestingly, on manual examina-
tion of PharmGKB database, the review article cited as evidence for
the relationship between lamovudine and ABCC4 gene (PubMed
ID: 16462814) does not contain either ABCC4 or MRP4 either in
the abstract or in the main body of the paper. Both of these names
(ABCC4 and MRP4), however, do appear in the References sectionof the article and the evidence for this relationship is actually con-
tained in these cited articles. This example points out a potential
limitation of using PharmGKB for mining drug–gene association
where the investigator that enters the data into PharmGKB has
the knowledge of the drug–gene relationship but does not neces-
sarily verify that the article provided as evidence contains the ac-
tual relationship rather than indirectly pointing to another
source of information. While this is a limitation, it can also be con-
sidered a strength as our methodology may be useful as a veriﬁca-
tion mechanism in helping investigators identify potential
problems with the evidence provided for the presence or absence
of a relationship between drugs and genes.
The focus of the current study was on determining if PharmGKB
could be used as a source of training data to automatically ﬁnd
gene targets related to a given drug. Since most of the gene and
gene product names are abbreviated, that introduces a large
amount of ambiguity. For this paper, we manually disambiguated
gene names to determine the impact of ambiguity on the accuracy
of gene target identiﬁcation. However, a number of word sense dis-
ambiguation algorithms targeted speciﬁcally to acronyms in clini-
cal and biomedical discourse [11–14] and gene names in particular
[10] have been developed. In future work it will be necessary to
integrate acronym and word sense ambiguity resolution as either
a pre- or a post-processing step during gene classiﬁcation.6. Conclusions
Our results indicate the feasibility of using PharmGKB as a
source of training data for machine learning to identify likely gene
targets for pathway driven approaches in pharmacogenomics. This
approach may be used iteratively to keep up with the growing vol-
ume of scientiﬁc literature and reduce the burden of manual
searches for potential gene targets. More importantly, using our
approach, pharmacogenomics investigators engaged in pathway-
driven analysis may also be able to identify gene targets that they
would not be able to identify using other standard search methods.Acknowledgments
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